Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders
NCT00846547
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
32
Enrollment
INDUSTRY
Sponsor class
Conditions
Autism Spectrum Disorders
Interventions
DRUG:
Arbaclofen
Sponsor
Seaside Therapeutics, Inc.